News
Article
ICYMI: Highlights From ESMO Congress 2023
Author(s):
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
Here are the ESMO 2023 conference highlights. Click here to catch up on all of our coverage from the conference.
5. TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared with standard of care in both non–small cell lung cancer (NSCLC) and hormone receptor–positive/HER2-negative breast cancer, according to findings presented at ESMO Congress 2023. In both presentations, trial investigators noted less toxicity with datopotamab deruxtecan compared with control interventions.
4. Dr Thomas Powles Discusses Impact of EV+P Therapy on Urothelial Carcinoma Treatment
Findings from the EV-302/KEYNOTE-A39 trial, presented at ESMO Congress 2023, suggest a new standard of care may be on the horizon in urothelial carcinoma for the first time in decades. Lead investigator Thomas Powles, MD, MBBS, MRCP, discussed the findings and the unmet need for therapies in metastatic urothelial carcinoma in an interview with The American Journal of Managed Care®.
3. Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC
Results presented at ESMO Congress 2023 demonstrated that the presence of brain metastases (BM) did not affect response to treatment with trastuzumab deruxtecan among patients with metastatic HER2 (ERBB2)-mutant (HER2m) NSCLC. A significant proportion of patients with HER2m NSCLC have BM at diagnosis, and post hoc pooled analyses of trastuzumab deruxtecan efficacy and safety from DESTINY-Lung01 and DESTINY-Lung02 suggest similar response rates regardless of BM status.
2. Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC
MARIPOSA and MARIPOSA-2 results showed improved PFS with amivantamab plus lazertinib vs osimertinib in the first-line setting and after progression on osimertinib in EGFR-mutated advanced NSCLC. In the MARIPOSA trial, the combination regimen reduced risk of progression or death by 30% vs osimertinib, and MARIPOSA-2 found that amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy alone after progression on osimertinib.
1. First in Decades: Enfortumab Vedotin + Pembrolizumab Beats Chemo in First-Line Metastatic Urothelial Cancer
Enfortumab vedotin plus pembrolizumab significantly improved outcomes compared with standard-of-care chemotherapy in patients with locally advanced metastatic urothelial cancer, marking the first time in decades that a new treatment outperformed chemotherapy in this disease setting. Both PFS and overall survival were significantly prolonged in the enfortumab vedotin plus pembrolizumab, suggesting this regimen may be a new standard of care for advanced metastatic urothelial cancer.
